Long-term subcutaneous treprostinil therapy evokes both survival benefits and continuous dose-dependent efficacy improvements in patients with pulmonary arterial hypertension

被引：0
|
作者：
Vachiery, JL [1 ]
Gautier, MT [1 ]
Huez, S [1 ]
Retailleau, K [1 ]
Naeije, R [1 ]
机构：
[1] Erasme Univ Hosp, Dept Cardiol, B-1070 Brussels, Belgium
来源：
CIRCULATION | 2003年 / 108卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1849
引用
收藏
页码：400 / 400
页数：1
相关论文
共 50 条
  • [31] Cutaneous findings in patients with pulmonary arterial hypertension receiving long-term epoprostenol therapy
    Myers, SA
    Ahearn, GS
    Selim, MA
    Tapson, VE
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 51 (01) : 98 - 102
  • [32] Long-term ambrisentan therapy provides sustained benefit in patients with pulmonary arterial hypertension
    Oudiz, Ronald J.
    CHEST, 2007, 132 (04) : 474S - 474S
  • [33] TRIUMPH 1: Long-Term Safety and Efficacy of Inhaled Treprostinil Sodium in Patients with Pulmonary Arterial Hypertension (PAH) - Two Year Follow-Up.
    Benza, R.
    Rubin, L.
    McLaughlin, V.
    Channick, R.
    Voswinckel, R.
    Tapson, V.
    Robbins, I.
    Olschewski, H.
    Seeger, W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [34] Short-term improvement in pulmonary hemodynamics is strongly predictive of long-term survival in patients with pulmonary arterial hypertension
    Tiede, Henning
    Sommer, Natascha
    Milger, Katrin
    Voswinckel, Robert
    Bandorski, Dirk
    Schermuly, Ralph T.
    Weissmann, Norbert
    Grimminger, Friedrich
    Seeger, Werner
    Ghofrani, Hossein A.
    PULMONARY CIRCULATION, 2013, 3 (03) : 523 - +
  • [35] EFFICACY AND SAFETY OF LONG-TERM PAH-SPECIFIC MONO-THERAPY WITH BOSENTAN IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
    Paramonov, V.
    Martynyuk, T.
    Chazova, I. E.
    JOURNAL OF HYPERTENSION, 2015, 33 : E195 - E195
  • [36] Von Willebrand factor independently predicts long-term survival in patients with pulmonary arterial hypertension
    Kawut, SM
    Horn, EM
    Berekashvili, KK
    Widlitz, AC
    Rosenzweig, EB
    Barst, RJ
    CHEST, 2005, 128 (04) : 2355 - 2362
  • [37] Integration of Clinical and Hemodynamic Parameters in the Prediction of Long-term Survival in Patients With Pulmonary Arterial Hypertension
    Kane, Garvan C.
    Maradit-Kremers, Hilal
    Slusser, Josh P.
    Scott, Chris G.
    Frantz, Robert P.
    McGoon, Michael D.
    CHEST, 2011, 139 (06) : 1285 - 1293
  • [38] Long-Term Efficacy of Oral Treprostinil in Subjects with Pulmonary Arterial Hypertension: FREEDOM-EV Open-Label Extension Study
    White, R. J.
    Broderick, M.
    Deng, C. Q.
    Grover, R.
    Holdstock, L.
    Khan, A.
    Bohns Meyer, G.
    Ng, B.
    Pulido Zamudio, T.
    Saib, I.
    Sepulveda, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [39] Long-term benefits of ambrisentan in patients with pulmonary arterial hypertension associated with connective tissue diseases.
    Badesch, D
    Zwicke, D
    Keogh, AM
    Galie, N
    Olschewski, H
    McGoon, MD
    McLaughlin, V
    Oudiz, R
    Frost, AE
    Simonneau, G
    Rubin, LJ
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S166 - S166
  • [40] Long-term benefits of ambrisentan in patients with pulmonary arterial hypertension: a comparison by etiology and baseline functional class
    Galiè, N.
    Frost, A.
    Keogh, A.
    Zwicke, D.
    Oudiz, R.
    Naeije, R.
    Olschewsky, H.
    Rubin, L.
    EUROPEAN HEART JOURNAL, 2005, 26 : 113 - 113
12345